Management of Hydroxyurea in Patients with Low Hemoglobin Requiring Blood Transfusion

Monitoring and Management Approach

For patients with sickle cell disease, a conservative hemoglobin threshold is advised, not exceeding 10 g/dL to reduce the risk of vaso-occlusion–related complications, as recommended by the American Society of Hematology 1
Monitor hemoglobin levels closely during and after transfusion, and for patients with SCD, aim for post-transfusion hemoglobin levels of 10-11 g/dL to minimize complications, according to the National Heart, Lung, and Blood Institute 2
Consider exchange transfusion rather than simple transfusion for patients with hemoglobin levels greater than 9-10 g/dL, as suggested by the American College of Physicians 2

For SCD patients with chronic kidney disease and worsening anemia, combination therapy with hydroxyurea and erythropoiesis-stimulating agents may be considered after transfusion and stabilization, as recommended by the European Hematology Association 1
When using combination therapy, maintain hemoglobin levels below 10 g/dL to reduce the risk of vaso-occlusive complications, according to the American Society of Hematology 1
Optimizing adherence to hydroxyurea therapy may help maximize fetal hemoglobin responses in SCD patients, as suggested by the National Institutes of Health 1